Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

CEPHEID

Develops, manufactures, and markets molecular systems and tests for institutions to perform sophisticated genetic tes... read more Featured Products: More products

Download Mobile App




Rapid Diagnostic Testing Evaluated for Chlamydia and Gonorrhea

By LabMedica International staff writers
Posted on 23 Nov 2016
Prolonged turnaround time of Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT) test results may delay time to notification and treatment of test-positive patients and result in unnecessary antimicrobial use in test-negative patients.

Nonculture methods, including nucleic acid amplification tests (NAAT), are widely available for the detection of genital NG/CT and are the preferred diagnostic tests, but with traditional NAAT, many health care facilities have a turnaround time between 1 and 4 days for results of NG/CT. This prolonged time to results impacts time to patient and partner notification as well as treatment for test-positive patients who do not receive empiric therapy.

Scientists at the Cleveland Clinic (Cleveland, OH, USA) and their colleagues evaluated the impact of NG/CT rapid diagnostic testing (RDT) in an urban emergency department (ED) on treatment appropriateness, time to notification, and cost. They tested 200 patients in December 2013–January 2014 by traditional methods and these were compared with 200 patients in December 2014–January 2015 by RDT. Samples utilized by the ED included male urine or urethral samples and female endocervical samples.

Traditional testing was performed using the Gen-Probe Aptima Combo 2 for NG/CT Assay (Hologic, Bedford, MA, USA). The RDTs were performed using the GeneXpert CT/NG assay (Cepheid, Sunnyvale, CA, USA). The RDT was validated compared with the traditional testing method with sensitivity and specificity. A total of 53 patient specimens were collected and tested including male and female first-catch urine samples, patient-collected vaginal swabs, and provider-collected endocervical swabs.

The scientists found that there was a significant increase in treatment appropriateness in the RDT group, 72.5% versus 60% and time to results notification was significantly faster with a median of 17.4 versus 51.5 hours. Availability of test result prior to discharge was associated with increased treatment appropriateness. They also reported that the RDT would save approximately USD 37,000 annually. Of the 200 patients tested in the RDT group, only 40 (20%) were present in the ED at the time their results became available.

The authors concluded that implementation of a RDT for NG/CT in the ED significantly improved initial treatment appropriateness by sparing unnecessary antimicrobial use, decreased time to patient notification, and resulted in cost savings. Having test results prior to patient discharge from the ED was independently associated with receiving appropriate treatment. Interventions to increase the proportion of tests resulted prior to discharge are warranted to improve utilization of the RDT. The findings of this evaluation support the use of the NG/CT RDT as a component of antimicrobial stewardship in the ED. The study was published on October 18, 2016, in the journal Diagnostic Microbiology and Infectious Disease.

Related Links:
Cleveland Clinic
Hologic
Cepheid

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Aspergillus Test
REALQUALITY Aspergillus
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.